Compare Bank Pan Indonesia Tbk (PNBN) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank Pan Indonesia Tbk vs Organon Pharma Indonesia Tbk. — how do they compare? Bank Pan Indonesia Tbk trades at Rp910 (market cap 21.81T, 1.3M 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Bank Pan Indonesia Tbk is far larger — about 208.9× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| PNBN | SCPI | |
|---|---|---|
Market Cap | 21.81T | 104.4B |
Volume | 1.3M | — |
Lot | 13.03K | — |
Turnover | 1.18B | — |
Average Price | 903.58 | — |
Value | 1.18B | — |
Indicative Equilibrium Price | 910 | — |
Indicative Equilibrium Volume | 1.43K | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank Pan Indonesia Tbk
PT Bank Pan Indonesia Tbk (the Bank) was established based on Deed No. 85 dated August 17, 1971 of notary Juliaan Nimrod Siregar gelar Mangaradja, S.H. Panin (Pan Indonesia) Bank was established by the merger of three small private banks. It was one of the first banks to be granted a foreign exchange license in 1972.
Read more on PNBN →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
